Efter to års behandling i dette studie, opstod der ALAT- normalisering og udetekterbar HBV DNA hos henholdsvis 30/ 69 (43%) og 32/ 68 (47%) af patienterne, og forbedring af nekroinflammatorisk score hos 18/ 49 (37%) af patienterne.
After two years of treatment in this study, ALT normalisation and undetectable HBV DNA occurred in 30/ 69 (43%) and 32/ 68 (47%) patients respectively and improvement in necroinflammatory score in 18/ 49 (37%) patients.